BMEA
Biomea Fusion, Inc.
$0.60
+2.58%
2026-10-23
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Key Fundamentals
Forward P/E
-1.40
EPS (TTM)
$-0.18
ROE
-164.1%
Profit Margin
0.0%
Debt/Equity
7.23
Price/Book
7.90
Beta
-0.24
Market Cap
$95.7M
Avg Volume (10D)
2.5M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$2.07
60D Low
$0.58
Avg Volume
2.2M
Latest Close
$0.60
Get breakout alerts for BMEA
Sign up for Breakout Scanner to receive daily notifications when BMEA triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Biomea Fusion, Inc. (BMEA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BMEA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BMEA operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.